Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized placebo-controlled, Phase 1b pharmacokinetic/pharmacodynamic trial of AM-201 co-administration with olanzapine in healthy volunteers

Next Previous
Trial Profile

A randomized placebo-controlled, Phase 1b pharmacokinetic/pharmacodynamic trial of AM-201 co-administration with olanzapine in healthy volunteers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Betahistine (Primary)
  • Indications Somnolence; Weight gain
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Auris Medical

    • Most Recent Events

    • 11 Oct 2019 According to an Auris Medical media release, the study will now proceed to the next higher and final dose level of 30 mg to be tested on 30 healthy volunteers. Data from larger dose cohort are anticipated towards the end of the first quarter of 2020.
    • 11 Oct 2019 Interim Results presented in an Auris Medical Media Release.
    • 15 Aug 2019 According to an Auris Medical media release, the Company expects top-line results from the trial in the coming weeks.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top